000			02221 a2200541 4500
005			20250513212202.0
264		0	_c20000816
008			200008s 0 0 eng d
022			_a1524-9557
024	7		_a10.1097/00002371-200005000-00010 _2doi
040			_aNLM _beng _cNLM
100	1		_aMerad, M
245	0	0	_aGeneration of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12). _h[electronic resource]
260			_bJournal of immunotherapy (Hagerstown, Md. : 1997) _c
300			_a369-78 p. _bdigital
500			_aPublication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAntibodies, Monoclonal _ximmunology
650	0	4	_aCarcinoma, Renal Cell _ximmunology
650	0	4	_aCytokines _ximmunology
650	0	4	_aDendritic Cells _xdrug effects
650	0	4	_aDrug Therapy, Combination
650	0	4	_aGranulocyte-Macrophage Colony-Stimulating Factor _ximmunology
650	0	4	_aHistocompatibility Antigens Class II _ximmunology
650	0	4	_aHumans
650	0	4	_aImmunologic Factors _xadministration & dosage
650	0	4	_aInterferon-alpha _xadministration & dosage
650	0	4	_aInterleukin-12 _xadministration & dosage
650	0	4	_aInterleukin-2 _xadministration & dosage
650	0	4	_aInterleukin-4 _ximmunology
650	0	4	_aKidney Neoplasms _ximmunology
650	0	4	_aLymphocyte Culture Test, Mixed
650	0	4	_aMelanoma _ximmunology
650	0	4	_aMonocytes _ximmunology
650	0	4	_aNeoplasm Metastasis
650	0	4	_aPeptides _ximmunology
650	0	4	_aRecombinant Proteins _xtherapeutic use
650	0	4	_aT-Lymphocytes _ximmunology
650	0	4	_aTetanus Toxoid
700	1		_aAngevin, E
700	1		_aWolfers, J
700	1		_aFlament, C
700	1		_aLorenzi, I
700	1		_aTriebel, F
700	1		_aEscudier, B
700	1		_aZitvogel, L
773	0		_tJournal of immunotherapy (Hagerstown, Md. : 1997) _gvol. 23 _gno. 3 _gp. 369-78
856	4	0	_uhttps://doi.org/10.1097/00002371-200005000-00010 _zAvailable from publisher's website
999			_c10790049 _d10790049